Skip to main content
OpenTrials
Completed

NCT Number: NCT05730855

Diagnostic Accuracy of lncRNA DQ786243 and miRNA146a in Saliva of Oral Potentially Malignant Lesions

The aim of this study is to evaluate salivary expression of lncRNA DQ786243 as a potential marker for diagnosis of oral potentially malignant lesions compared to normal controls and its effect on salivary expression of miRNA146a.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Potentially Malignant Lesions Head and Neck Neoplasms Leukoplakia Leukoplakia, Oral Lichen Planus Lichen Planus, Oral Lichenoid Eruptions Mouth Diseases Mouth Neoplasms Neoplasms Neoplasms by Site Oral Lichen Planus Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Precancerous Conditions Skin Diseases Skin Diseases, Papulosquamous Skin and Connective Tissue Diseases Stomatognathic Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Fayoum University

Al Fayyum, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • participants will be divided into 3 groups:

Group I: patients suffering from oral lichen planus Group II: patients suffering from leukoplakia Group III: healthy subjects who are systemically free, non-smokers, and not suffering from any oral mucosal lesions.

Exclusion criteria

  • Subjects taking any drugs inducing any changes that could affect the salivary flow.
  • Pregnant females.
  • Subjects have any allergies, infectious diseases or active dental abscesses during one month before saliva sampling.
  • Patients receiving any drugs related to the oral lesions in the past 6 month prior to sample collection.

Treatment and study plan

Real-time Polymerase Chain Reaction technique

Diagnostic Test

Real-time Polymerase Chain Reaction technique

Primary outcomes

  1. salivary expression of lncDQ786243 in OLP, Leukoplakia, control

    Time frame: 2 months

Secondary outcomes

  1. salivary expression of miRNA146a in OLP, Leukoplakia, control

    Time frame: 2 months

Sponsors and collaborators

Lead sponsor

Fayoum University

Other

Registry information

Important dates

Study start
2022
Primary completion
2022
Study completion
2023
First posted
Feb 16, 2023
Registry last updated
Sep 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.